Arvinas Stock Quote ARVN - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

34.00

Bid

33.00

Ask

34.67

Volume

0.00 Day's Range 0.00

13.57 52 Week Range 53.08

Market Cap

2.311B

Previous Close

34.00

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

785,108

Shares Outstanding

68,083,928

Dividend Yield

PE Ratio

-6.29

Earnings Per Share (EPS)

-5.39

Revenue

78.5M

Net Profit

-367.3M

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.arvinas.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $34. Over the last year, Arvinas shares have traded in a share price range of $ 13.57 to $ 53.08.

Arvinas currently has 68,083,928 shares outstanding. The market capitalization of Arvinas is $2.31 billion. Arvinas has a price to earnings ratio (PE ratio) of -6.29.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.055	-0.161503450301	34.055	35.865	32.6101	718898	34.31238568	CS
4	-7.6	-18.2692307692	41.6	41.98	32.6101	588159	36.86101352	CS
12	-5.36	-13.6178861789	39.36	53.08	32.6101	785108	44.03223887	CS
26	18.28	116.284987277	15.72	53.08	13.57	794312	35.96523428	CS
52	5.46	19.1310441486	28.54	53.08	13.57	603112	32.01025708	CS
156	-32	-48.4848484848	66	108.465	13.57	501750	47.79375431	CS
260	11.11	48.5364788117	22.89	108.465	13.57	486936	47.04944829	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
MTCMMTec Inc	$ 2.24 (43.59%)	6.07M
OPRTOportun Financial Corporation	$ 3.16 (40.44%)	11.71M
SHIMShimmick Corporation	$ 3.05 (35.56%)	1.19M
HKITHitek Global Inc	$ 1.35 (32.35%)	411.78k
ABEOAbeona Therapeutics Inc	$ 3.39 (-53.94%)	5.51M
GWAVGreenwave Technology Solutions Inc	$ 0.0696 (-44.89%)	37.05M
LICNLichen China Limited	$ 0.56 (-42.19%)	6.61M
MLECMoolec Science SA	$ 1.71 (-30.77%)	3.16M
VAXXVaxxinity Inc	$ 0.1971 (-26.89%)	2.11M
CYNCYNGN Inc	$ 0.113 (-6.61%)	326.58M
PEGYPineapple Energy Inc	$ 0.0561 (22.49%)	185.74M
SQQQProShares UltraPro Short QQQ	$ 11.91 (-4.49%)	139.15M
NIVFNewGenIvf Group Ltd	$ 2.23 (74.22%)	137.08M
TSLATesla Inc	$ 144.68 (1.85%)	124.55M